PEAVision™ is a patent applied nutraceutical formulation developed through translational pharmacology to support ocular health and address the molecular mechanisms involved in Primary Open-Angle Glaucoma (POAG).

It is designed to reduce intraocular pressure, improve retinal microcirculation, and protect optic nerve cells through synergistic action.

PEAVision™ contains a scientifically validated combination of:

• Palmitoylethanolamide (PEA): A naturally occurring bio-regulator known for its neuroprotective and anti-inflammatory properties.
• Forskolin: Extracted from Coleus forskohlii, it promotes cyclic AMP production and supports natural IOP reduction.
• Rutin: A potent antioxidant bioflavonoid that enhances vascular health and reduces oxidative damage.

PEAVision™ is classified as a nutraceutical innovation, not a pharmaceutical drug. It is developed using pharmacological research standards but is intended as a scientifically formulated nutraceutical product that aligns with global dietary supplement and safety guidelines.

Yes. PEAVision™ has undergone multiple preclinical and clinical studies, demonstrating safety, tolerability, and efficacy in reducing intraocular pressure and supporting retinal ganglion cell protection. All results are documented under internationally accepted research protocols.

Absolutely. The formulation is supported by peer-reviewed research, laboratory studies, and clinical validation data. These findings confirm its role in neuroprotection, antioxidation, and IOP modulation, aligning with modern ocular pharmacology principles.

Its uniqueness lies in its multimodal mechanism of action — addressing glaucoma not through a single pathway, but through a synergistic combination of molecular effects:

• Reducing oxidative stress
• Modulating inflammation
• Improving aqueous humor dynamics
• Protecting retinal ganglion cells

This integrated approach differentiates PEAVision™ from conventional single-target therapies.

Yes. All ingredients in PEAVision™ have been evaluated for long-term safety in clinical and preclinical environments. No systemic, hepatic, renal, or ocular toxicity has been observed across multiple studies.

For research reference and nutraceutical development purposes, the recommended dose evaluated in trials was 1 tablet twice daily after meals. This information is provided strictly for documentation and educational purposes, not as medical advice.

No. PEAVision™ is not a substitute for prescribed medical therapy. However, studies show it may have synergistic benefits when used alongside conventional anti-glaucoma treatments — improving outcomes while maintaining safety.

PEAVision™ follows global nutraceutical and safety compliance frameworks, with patent applied filed and documentation aligned with international research and intellectual property standards. It is not a pharmaceutical drug and does not claim to treat or cure diseases.

Yes. PEAVision™ is a patent-applied formulation, ensuring that its composition, research, and claims remain the intellectual property of its developers. The patent safeguards its unique formulation and molecular synergy from replication or misuse.

Yes. Licensing and distribution partnerships are available under specific regulatory compliance frameworks. Organizations or researchers interested in collaborations can contact partnerships@peavision.com for documentation and terms.

PEAVision™ has been developed through collaborative scientific research by experts in pharmacology, ophthalmology, and nutraceutical science. Its foundation lies in translational research bridging laboratory science with real-world ocular health benefits.

You can request access to PEAVision™’s published research, white papers, and preclinical documentation by contacting our scientific department at research@peavision.com.

We welcome collaboration with:

• Universities and research institutions
• Nutraceutical and pharmaceutical developers
• Regulatory authorities
• Ophthalmology and pharmacology experts

Collaboration inquiries can be submitted through the Contact Page or by writing to collaborate@peavision.com.